Meeting
2021 Genitourinary Cancers Symposium
CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC).
Authors
Amin Nassar
Brigham and Women's Hospital, Boston, MA
Amin Nassar , Elio Adib , Elie W. Akl , Sarah Abou Alaiwi , Pier Vitale Nuzzo , Tarek H. Mouhieddine , Guru Sonpavde , Robert I. Haddad , Marios Giannakis , F. Stephen Hodi , Toni K. Choueiri , David J. Kwiatkowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 475)
DOI
10.1200/JCO.2021.39.6_suppl.475
Abstract #
475
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang
Poster
2021 Gastrointestinal Cancers Symposium
Genomic profiling of gastrointestinal cancers by comprehensive tumor-normal sequencing.
First Author: Fadel S. Alyaqoub
Poster
2023 ASCO Annual Meeting
Assessing tumor-infiltrating immune cells and outcomes with cisplatin- versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum-treated UC cohorts.
First Author: Konrad Stawiski
Poster
2023 ASCO Annual Meeting
C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.
First Author: Alexander B Karol